(redirected from I-131)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to iodine-131

heavy radioactive isotope of iodine with a half-life of 8 days

References in periodicals archive ?
The diagnosis of severe thyrotoxicosis also required radioactive iodine (I-131) uptake exceeding 30% at 4 or 24 hours after administration of I-131.
All of the patients were treated with 10-20 mCi of I-131 and were evaluated for any evidence of thyroid storm.
Because of its 97% success rate and very low risk of side effects, Radioiodine I-131 treatment has become the treatment of choice for veterinarians worldwide.
As of 10 May, the restriction on the consumption of drinking water relating to I-131 - which had been applied since 1 April as a precautionary measure for one remaining location (the village of Iitate in Fukushima prefecture), and only for infants - was lifted.
Administration of KI decreases the thyroid's uptake of I-131, said Dr.
In Fukushima prefecture, levels in 212 (93%) of the 228 samples reported were below the regulation values for I-131 and radioactive caesium.
Since 1 April there has been one remaining restriction on the consumption of drinking water relating to I-131 (with a limit of 100 Bq/L), which is applicable only for one village in the Fukushima prefecture and only for infants.
Studies using I-131 tagged albumin have demonstrated plasma volume expansion in more than 50% of patients in whom clinical volume overload was not recognized.
I-131 deposition was reported for one prefecture on 26 April, with a value of 3.
A phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I-131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group protocol S9911.
On 19 April, deposition of I-131 was detected in 13 prefectures, ranging from 1.
radiolabeled antibodies) for the BEXXAR dosimetric dose using Iodine I-131 tositumomab.
I-131 sodium iodide (capsule) or equivalent, 2,846 units .
The activities for I-131, Cs-134 and Cs-137 were 220 Bq/cm3, 88 Bq/cm3 and 93 Bq/cm3 respectively.
Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, and MDS Nordion today announced that the companies have signed a new seven year manufacturing agreement in which MDS Nordion will continue to radiolabel the antibody in BEXXAR(R) (tositumomab and iodine I-131 tositumomab) therapy.